NR2F6 and neoplasm: Upregulation produces effector T cells that are unable to achieve an adequate immune response to cancer, and NR2F6 downregulation sensitizes tumors to established PD-1/PD-L1 axis blockade, which produces a potent synergistic effect with established surface checkpoint blockade (PD-L1, CTLA-4) to inhibit tumor progression [30].